🔍

GLAND - Gland Pharma

📊 NSE: GLAND 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/13/2025 22:22

📢 Recent Corporate Announcements

Gland Pharma Schedules Non-Deal Roadshow with Elara (USA) for March 18-20, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Mar 2026, 03:43 PM

Gland Pharma Limited has announced a Non-Deal Roadshow (NDR) scheduled to take place from March 18 to March 20, 2026. The company will engage in one-on-one meetings with institutional investors and analysts, facilitated by Elara (USA). This initiative is part of the company's regular investor relations outreach to discuss business performance and strategy with the international investment community.

Three-day Non-Deal Roadshow (NDR) scheduled from March 18 to March 20, 2026.
Meetings will be conducted in a one-on-one format with institutional investors and analysts.
The roadshow is organized in collaboration with Elara (USA) targeting international stakeholders.
The schedule is subject to change based on the exigencies of the company or investors.

💡 No immediate action is required as this is a routine investor engagement; however, investors should watch for any subsequent analyst reports that may provide updated perspectives on the company.

Gland Pharma Schedules One-on-One Meeting with Sundaram Asset Management

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 11 Mar 2026, 05:32 PM

Gland Pharma Limited has announced a scheduled interaction with Sundaram Asset Management set for March 16, 2026. The meeting is categorized as a one-on-one session to discuss the company's business and performance. This disclosure is a routine regulatory requirement under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Investors should note that such meetings are standard practice for institutional engagement and typically do not involve the disclosure of unpublished price-sensitive information.

One-on-one meeting scheduled with Sundaram Asset Management on March 16, 2026
Official intimation filed with BSE and NSE on March 11, 2026
Meeting is subject to change based on exigencies from either party
Compliance maintained under Regulation 30 of SEBI LODR Regulations

💡 No immediate action is required as this is a routine investor relations activity. Investors may monitor the company's website for any subsequent investor presentations or transcripts related to this meeting.

Gland Pharma Schedules Institutional Investor Meetings and Plant Visit in March 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Mar 2026, 05:22 PM

Gland Pharma has announced a series of interactions with institutional investors and analysts scheduled between March 12 and March 17, 2026. The schedule includes a plant visit arranged by Investec and one-on-one meetings with major funds like SBI Mutual Fund and Capital World Investors. These interactions are part of the company's regular engagement with the financial community to discuss business operations. While these meetings are routine, they often signal management's openness to discussing long-term strategy with key stakeholders.

Plant visit for investors arranged by Investec scheduled for March 12, 2026
One-on-one meeting with SBI Mutual Fund confirmed for March 13, 2026
Group meeting organized by Investec also set for March 13, 2026
One-on-one interaction with Capital World Investors scheduled for March 17, 2026

💡 No immediate action is required as this is a routine regulatory disclosure. Investors should watch for any subsequent investor presentations or transcripts that may provide updated guidance on the company's manufacturing outlook.

Gland Pharma to Attend Group Investor Meeting Arranged by Goldman Sachs on March 5

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Feb 2026, 03:09 PM

Gland Pharma Limited has announced a group meeting with analysts and institutional investors scheduled for March 05, 2026. The meeting is being organized by Goldman Sachs and is part of the company's regular investor relations activities. This disclosure is made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Such meetings typically provide a platform for management to discuss business outlook and performance with the investment community.

Group meeting with analysts and institutional investors scheduled for March 05, 2026
Meeting is being organized by Goldman Sachs
Disclosure submitted under SEBI (LODR) Regulations, 2015
The schedule is subject to change due to exigencies on the part of the company or investors

💡 No immediate action is required as this is a routine disclosure; however, investors should monitor for any post-meeting transcripts or presentations for updates on business strategy.

Gland Pharma to Meet Renaissance Investment Managers on February 25, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 20 Feb 2026, 03:05 PM

Gland Pharma Limited has announced a one-on-one meeting with Renaissance Investment Managers scheduled for February 25, 2026. This interaction is part of the company's routine engagement with institutional investors to discuss business updates. The disclosure is made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Investors should note that the schedule is subject to change based on the availability of either party.

One-on-one meeting scheduled with Renaissance Investment Managers.
The meeting is set to take place on February 25, 2026.
Disclosure filed under SEBI (LODR) Regulations, 2015.
The schedule remains subject to change due to exigencies.

💡 No immediate action is required as this is a routine investor meeting. Investors may look for any subsequent investor presentations or transcripts that might be released following the interaction.

Gland Pharma to Meet Mirae Asset Investment Managers on February 23, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 18 Feb 2026, 12:22 PM

Gland Pharma Limited has scheduled a one-on-one meeting with Mirae Asset Investment Managers on February 23, 2026. This interaction is part of the company's routine engagement with institutional investors to discuss business updates. The meeting schedule was disclosed to the exchanges on February 18, 2026, in compliance with SEBI (LODR) Regulations. Such meetings typically involve discussions on the company's general business outlook and industry trends.

One-on-one meeting scheduled with Mirae Asset Investment Managers.
The meeting is set to take place on February 23, 2026.
Disclosure made in compliance with SEBI (LODR) Regulations, 2015.
The schedule is subject to change due to exigencies on either side.

💡 This is a routine corporate event; no specific action is needed. Investors should monitor the company's website for any investor presentations shared during this period.

Gland Pharma Appoints Dr. Jitendra Gangwal as VP of R&D to Lead Complex Product Development

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 18 Feb 2026, 12:06 PM

Gland Pharma has appointed Dr. Jitendra Gangwal as Vice-President of Research and Development, effective February 18, 2026. Dr. Gangwal brings over 24 years of experience in pharmaceutical R&D, having previously held leadership roles at Dr. Reddy’s, Glenmark, and Alkem Laboratories. His track record includes the development of 55+ products and filing 10+ patents, specifically in complex delivery systems like liposomes and peptides. This strategic hire is intended to bolster Gland Pharma's pipeline of high-value complex injectables for regulated global markets.

Dr. Jitendra Gangwal appointed as VP (R&D) with over 24 years of pharmaceutical experience.
Developed 55+ products across injections, ophthalmics, inhalation, and nasal routes.
Filed 10+ patents and led multiple 505(b)(2) and ANDA filings in previous roles.
Expertise in complex parenterals, nano-crystals, liposomes, and advanced polymer-based delivery systems.

💡 Investors should view this as a positive move to strengthen the company's core R&D capabilities. Monitor the pace of new ANDA filings and complex product approvals over the next 12-18 months to gauge the impact of this leadership change.

Gland Pharma Schedules One-on-One Investor Meeting with Investec on February 12

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Feb 2026, 05:06 PM

Gland Pharma Limited has announced a scheduled interaction with institutional investors. The company will hold a one-on-one meeting with Investec on February 12, 2026. This disclosure is a routine compliance filing under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Such meetings are standard practice for management to engage with the investment community regarding business outlook and performance.

One-on-one meeting scheduled with Investec.
The meeting is set to take place on February 12, 2026.
Filing made in compliance with SEBI LODR Regulation 30.
Schedule is subject to change based on exigencies of either party.

💡 No immediate action is required as this is a routine investor meeting; however, investors should watch for any post-meeting presentations or transcripts released to the exchanges.

Gland Pharma Gets USFDA Approval for Zoledronic Acid Injection; US Market Size $6.7 Million

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 06 Feb 2026, 11:11 AM

Gland Pharma has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Zoledronic Acid Injection (4 mg/100 mL) in single-dose bags. The product is indicated for treating Hypercalcemia of Malignancy, Multiple Myeloma, and Bone Metastases of Solid Tumors. According to IQVIA data, the product's US market sales were approximately USD 6.7 million for the twelve months ending November 2025. This approval strengthens Gland's sterile injectable portfolio in the key US market.

Received USFDA approval for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/mL) Single-Dose Bags
Product is bioequivalent and therapeutically equivalent to the reference listed drug by InfoRLife
Target indications include Hypercalcemia of Malignancy and Multiple Myeloma
US market sales for the product were approximately USD 6.7 million for the year ending November 2025

💡 Investors should view this as a positive incremental addition to Gland's US portfolio, though the individual market size is modest. Monitor the company's ability to maintain its track record of USFDA approvals and market share gains in the generic injectables space.

Gland Pharma Q3 FY26 Revenue Up 22% to ₹1,695 Cr; Plans ₹2,000 Cr Capex Over 5 Years

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 05:02 PM

Gland Pharma reported a strong Q3 FY26 with revenue growing 22% YoY to INR 16,954 million and adjusted EBITDA rising 25% to INR 4,490 million. The company announced a significant five-year capex plan of INR 2,000 crores focused on complex injectables, BFS, and ophthalmic lines. A major capacity expansion for cartridge fill and finish from 40 million to 140 million units is underway to target the GLP-1 and peptide markets. Management also noted a visible EBITDA turnaround at Cenexi and maintained a high R&D spend of 5.4% of revenue.

Revenue grew 22% YoY to INR 16,954 million in Q3 FY26, with 9M FY26 revenue up 12%.
Adjusted EBITDA increased 25% YoY to INR 4,490 million, reflecting better operating leverage.
Announced INR 2,000 crore capex over the next 5 years for brownfield expansions and CDMO contracts.
Expanding cartridge fill and finish capacity by 250% from 40 million to 140 million units.
Filed 9 ANDAs and launched 9 new products in the U.S. market during the quarter.

💡 Investors should monitor the execution of the ₹2,000 Cr capex plan and the ramp-up of the expanded cartridge capacity, which are critical for long-term value growth. The turnaround in Cenexi and strong EBITDA growth suggest improving operational efficiency and a positive outlook for the stock.

Gland Pharma Schedules Multiple Investor Meetings and Roadshows in February 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 01 Feb 2026, 05:29 AM

Gland Pharma Limited has announced a series of institutional investor interactions scheduled between February 4 and February 10, 2026. The company will participate in a Non-Deal Roadshow (NDR) with Motilal Oswal and attend three major financial conferences hosted by JM Financial, Systematix, and Axis Capital. These meetings involve both one-on-one and group discussions, providing management an opportunity to engage with the investment community. Such disclosures are routine regulatory requirements and typically do not involve the sharing of unpublished price-sensitive information.

Non-Deal Roadshow (NDR) with Motilal Oswal scheduled for February 4, 2026, featuring one-on-one meetings.
Participation in JM Financial India Xchange Conference on February 5, 2026, for group and individual sessions.
Attendance at Systematix India Annual Conference on February 9, 2026.
Participation in Axis Capital's Flagship India Conference on February 10, 2026.

💡 Investors should monitor for any investor presentations or transcripts that the company may release following these meetings for insights into management's outlook. No immediate trading action is required as this is a routine corporate event.

Gland Pharma COO Satnam Singh Loomba to Retire Effective March 31, 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 29 Jan 2026, 04:12 PM

Gland Pharma Limited has announced that Mr. Satnam Singh Loomba will retire from his position as Chief Operating Officer (COO) on March 31, 2026. The retirement is due to superannuation, marking the end of his tenure which began on May 1, 2024. As a key member of the senior management, his departure is a planned transition. The company has placed on record its appreciation for his leadership during his nearly two-year stint with the firm.

Mr. Satnam Singh Loomba to retire as COO effective March 31, 2026
Retirement is attributed to superannuation (attaining retirement age)
Mr. Loomba served as COO of Gland Pharma since May 1, 2024
The transition is being handled under SEBI Listing Obligations and Disclosure Requirements

💡 Investors should monitor the company's upcoming announcements regarding the appointment of a successor to ensure operational continuity. This is a routine retirement and does not signal internal distress.

Gland Pharma Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 28 Jan 2026, 09:15 PM

Gland Pharma Limited has officially released the audio recording of its earnings conference call for the quarter and nine months ended December 31, 2025. The call was conducted on January 28, 2026, at 18:30 IST, following the disclosure of the company's financial results. This filing is a standard regulatory requirement under SEBI (LODR) Regulations to ensure all investors have access to management discussions. The recording provides insights into the company's performance and strategic outlook for the fiscal year 2026.

Earnings call for Q3 and 9M FY26 held on January 28, 2026, at 18:30 IST.
Audio recording link (https://glandpharma.com/images/Q3_FY26.mp3) made available for public access.
Compliance with Regulations 30 and 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The disclosure follows the initial earnings announcement dated January 09, 2026.

💡 Investors should listen to the recording to understand management's commentary on business growth, margin sustainability, and the progress of international operations.

Gland Pharma Q3 FY26: Adj. PAT Surges 37% YoY to ₹2,797 Mn; Revenue Up 22%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 28 Jan 2026, 05:27 PM

Gland Pharma delivered a strong performance in Q3 FY26, with consolidated revenue growing 22% YoY to ₹16,954 Mn. The company's Adjusted PAT saw a significant jump of 37% YoY to ₹2,797 Mn, supported by a recovery in margins. Adjusted EBITDA margins improved to 26% from 23% in the previous quarter, reflecting better operational efficiency. The core base business remains the primary driver, contributing ₹11,790 Mn to revenue with a healthy 28% PAT margin.

Consolidated Revenue from operations grew 22% YoY and 14% QoQ to ₹16,954 Mn
Adjusted PAT increased 37% YoY to ₹2,797 Mn, with a sharp 52% sequential growth
Adjusted EBITDA margin expanded to 26% in Q3 FY26 from 23% in Q2 FY26
Base business revenue grew 16% YoY to ₹11,790 Mn with an Adjusted PAT of ₹3,274 Mn
R&D expenditure for the base business stood at ₹650 Mn, accounting for 5.5% of its revenue

💡 The strong double-digit growth in both top-line and bottom-line suggests a robust recovery in the injectable segment. Investors should maintain a positive outlook given the margin expansion and steady performance of the core business.

Gland Pharma Q3 FY26: Revenue Up 22% YoY, Adj. PAT Surges 37% to ₹2,797 Mn

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 28 Jan 2026, 05:23 PM

Gland Pharma reported a robust performance for Q3 FY26, with consolidated revenue growing 22% YoY to ₹16,954 million. The growth was primarily driven by strong execution in the US and Europe, alongside the Cenexi business reaching breakeven. Adjusted PAT witnessed a significant 37% YoY increase to ₹2,797 million, while Adjusted EBITDA margins remained healthy at 26%. Management highlighted consistent execution and a ramp-up in CDMO contracts as key drivers for future momentum.

Consolidated Revenue from operations increased 22% YoY to ₹16,954 million.
Adjusted PAT grew by 37% YoY to ₹2,797 million, with margins improving to 16%.
European market revenue surged 54% YoY to ₹4,071 million, while US revenue grew 19% to ₹8,685 million.
Adjusted EBITDA stood at ₹4,490 million, up 25% YoY, with a margin of 26%.
R&D investments increased to ₹650 million from ₹437 million in the previous year.

💡 The results indicate a strong recovery in profitability and successful integration of the Cenexi acquisition. Investors may consider this a positive signal for long-term growth, especially with the US and European markets showing double-digit growth.

View All GLAND Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 6% YoY to INR 14,869 million in Q2 FY26. The US segment grew 8% YoY to INR 8,005 million. Other regulated markets (Europe, Canada, Australia, NZ) grew 18% YoY in H1 FY26. Cenexi revenue grew 10% YoY in Euro terms to EUR 88 million for H1 FY26. ROW own product sales grew 19% YoY, though offset by a 53% decline in tech transfer/CMO revenue.

Geographic Revenue Split

US market accounts for approximately 54% of Q2 revenue (INR 8,005 million). ROW market contributed INR 1,635 million (approx. 11%). India market generated INR 665 million (approx. 4.5%). Other regulated markets and Cenexi operations in Europe constitute the remaining balance.

Profitability Margins

Consolidated EBITDA margin stood at 21% for Q2 FY26. The base business (excluding Cenexi) maintained a high adjusted EBITDA margin of 36% in H1 FY26. Cenexi's EBITDA losses narrowed from EUR 11 million to EUR 5 million YoY in H1 FY26, showing a positive trend toward the Q3 breakeven target.

EBITDA Margin

Consolidated EBITDA was INR 3,139 million (21% margin), up 6% YoY. Adjusted EBITDA for H1 FY26 was INR 7,092 million (24% margin). The margin is currently suppressed by Cenexi's operational losses but supported by the core business's 36% margin profile.

Capital Expenditure

Capex is strictly allocated to high ROCE initiatives including CDMO expansion, GLP-1 capacity, and complex injectable capabilities. Specific INR values for total planned capex were not disclosed in the available documents.

⚙️ Operational Drivers

Capacity Expansion

Expanding complex injectable manufacturing and adding GLP-1 capacity. A dedicated line for a large product is starting next quarter. Cenexi is targeting a EUR 50 million revenue run rate to achieve EBITDA breakeven.

Manufacturing Efficiency

Focusing on yield improvement and waste reduction through digitization. Cenexi is undergoing headcount optimization and finance/IT back-office integration with India to capture synergies.

📈 Strategic Growth

Expected Growth Rate

19%

Growth Strategy

Growth is driven by a shift toward a differentiated complex portfolio, including CDMO launches of auto-injectors and pen-device systems. The company is expanding into GLP-1 capacity and complex injectables. Turnaround of Cenexi via price increases and product mix optimization is expected to contribute to margin expansion. New product launches like Dalba (this quarter) and Cangrelor (future) are key drivers.

Products & Services

Injectables, CDMO services, auto-injectors, pen-device systems, and specialty segment medicines including Dalba and Cangrelor.

Brand Portfolio

Gland Pharma, Cenexi.

New Products/Services

New launches contributed 7% to US growth in Q2 FY26. Key upcoming products include Dalba and complex injectables using new manufacturing technologies.

Market Expansion

Expanding presence in regulated markets (US/Europe) through CDMO contracts and increasing penetration in ROW markets where own product sales grew 19%.

Strategic Alliances

CDMO partnerships with major firms like Eli Lilly and Dr. Reddy's (DRL) for tech transfer and manufacturing.

🌍 External Factors

Industry Trends

The industry is shifting toward complex injectables and CDMO outsourcing. Gland is positioning itself as a global innovation-led injectable company, moving away from simple generics to high-margin niche formulations to counter competitive pricing.

Competitive Landscape

Operates in a competitive pricing environment in the US. Competitors include other global injectable players and CDMOs.

Competitive Moat

Moat is built on complex manufacturing capabilities (auto-injectors, pen-devices) and a high-margin CDMO model. This is sustainable because these technologies are harder to replicate than standard injectable lines, creating higher switching costs for partners.

Macro Economic Sensitivity

Sensitive to the US regulatory and licensing environment; a 'wait and see' approach by US partners has slowed licensing, reducing milestone revenue by approximately 44% from normal levels.

Consumer Behavior

Increased demand for advanced delivery systems like auto-injectors and pen-devices in the specialty segment.

⚖️ Regulatory & Governance

Industry Regulations

Fontenay site GMP certification renewed through end of 2026 following an ANSM inspection in July. Compliance with high quality standards is maintained to ensure margin resilience in regulated markets.

⚠️ Risk Analysis

Key Uncertainties

Milestone revenue timing and US licensing slowdowns pose a 40-50% risk to the normal milestone revenue run rate. Cenexi's ability to hit the EUR 50 million Q3 target is critical for consolidated breakeven.